+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID06628908

Phase 3 Randomized Study Comparing Suzetrigine, Pregabalin, and Placebo for Pain in Diabetic Peripheral Neuropathy

Led by Vertex Pharmaceuticals Incorporated · Updated on 2026-10-15

1100

Participants Needed

76

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness, safety, and tolerability of Suzetrigine SUZ in adults with pain caused by diabetic peripheral neuropathy DPN. This Phase 3 clinical trial compares Suzetrigine to Pregabalin and placebo to better understand how these treatments impact pain associated with DPN. Participants will be randomly assigned to one of three groups receiving Suzetrigine tablets, Pregabalin capsules, or a placebo that matches either Suzetrigine or Pregabalin. The study is double-blinded and lasts 12 weeks during which participants take the assigned oral medication. The trial actively monitors participants responses to treatment over this period. Participants will be assessed for changes in their daily pain levels using the Numeric Pain Rating Scale NPRS throughout the 12 weeks. Additional evaluations include physical health status measured by the SF-36 questionnaire. Researchers will monitor safety and tolerability during the trial. The total participation duration spans up to 12 weeks from baseline to final assessment.

CONDITIONS

Brief Title

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Research Team

M

Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here